Topics

NeuroVive Pharmaceutical - Steady progress with core assets

10:58 EDT 12 Sep 2019 | FinanzNachrichten

NeuroVive's core R&D assets in genetic mitochondrial diseases have made steady progress over the past several months. Notable newsflow includes KL1333 proceeding to the second part of its study and...

Original Article: NeuroVive Pharmaceutical - Steady progress with core assets

NEXT ARTICLE

More From BioPortfolio on "NeuroVive Pharmaceutical - Steady progress with core assets"

Quick Search